Average Co-Inventor Count = 5.4

ph-index = 15

Forward Citations = 603(Granted Patents)

Forward Citations (Not Self Cited) = 601(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Vernon Hills, IL (US) (1990 - 1993)
Buffalo Grove, IL (US) (1993)
Mason, OH (US) (1999)
Cincinatti, OH (US) (2001)
Cincinnati, OH (US) (1994 - 2008)

Company Filing History:

46 out of 17,167

The Procter Gamble Company

patents

10 out of 4,179

Abbott Laboratories Corporation

patents

2 out of 308

The Proctor 'gamble Company

patents

4. 1 out of 832,843

Other

patents

Years Active: 1990-2008

Loading Chart...

Areas of Expertise:

Cytokine Inhibitors

Metalloprotease Inhibitors

Prostaglandin Analogs

Pyrazolone Compounds

Heterocyclic Compounds

Aromatic Compounds

Hydroxamic Acids

Interleukin Converting Enzyme

Analgesic Compounds

Triazole Compounds

Pyrrolidine Hydroxamate

Inflammatory Cytokines

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7449474 - Tri-substituted ureas as cytokine inhibitors (2008-11-11),

2. 7402589 - Tri-substituted ureas as cytokine inhibitors (2008-07-22),

3. 7319102 - Pyrrolo[2,3-d]pyrimidine cytokine inhibitors (2008-01-15),

4. 7256196 - Purine cytokine inhibitors (2007-08-14),

5. 7138395 - Interleukin-1β converting enzyme inhibitors (2006-11-21),

6. 7087615 - 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia (2006-08-08),

7. 7041696 - Interleukin-1β converting enzyme inhibitors (2006-05-09),

8. 7001899 - Interleukin converting enzyme inhibitors (2006-02-21),

9. 6949545 - Heterocyclic side chain containing, n-substituted metalloprotease inhibitors (2005-09-27),

10. 6919346 - Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity (2005-07-19),

11. 6872742 - Substituted cyclic amine metalloprotease inhibitors (2005-03-29),

12. 6858628 - Substituted cyclic amine metalloprotease inhibitors (2005-02-22),

13. 6852751 - Difluorobutyric acid metalloprotease inhibitors (2005-02-08),

14. 6821971 - Fused pyrazolone compounds which inhibit the release of inflammatory cytokines (2004-11-23),

15. 6790846 - Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity (2004-09-14),

Title: Innovator Spotlight: Biswanath De - Pioneering Cytokine Inhibitor Technologies

Introduction: Meet Biswanath De, a prolific inventor based in Cincinnati, OH, with an impressive portfolio of 59 patents. His groundbreaking work in developing cytokine inhibitors is revolutionizing the treatment of inflammatory diseases.

Latest Patents: Biswanath De's latest patents showcase his expertise in cytokine inhibition. The invention of 1,1,3-tri-substituted ureas as cytokine inhibitors represents a significant breakthrough in targeting inflammatory cytokines linked to various disease states in humans and higher mammals.

Career Highlights: Biswanath De has made significant contributions to companies like The Procter & Gamble Company and Abbott Laboratories Corporation. His innovative research and patented technologies have led to advancements in the field of biochemistry and pharmaceuticals.

Collaborations: Throughout his career, Biswanath De has collaborated with esteemed professionals in the industry, including Michael G Natchus and Neil Gregory Almstead. These partnerships have played a crucial role in the development and commercialization of his groundbreaking inventions.

Conclusion: Biswanath De's dedication to innovation and his pioneering work in cytokine inhibition have earned him a reputation as a leading figure in the field of biochemistry. His patents not only demonstrate his technical expertise but also highlight his commitment to improving healthcare outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com